Aurisco Pharmaceutical Co Ltd

Aurisco announced that its wholly owned subsidiary Yangzhou Aurisco received a notification letter and on-site inspection report from the U.S. FDA, confirming that its quality management system meets U.S. FDA standards and successfully passed the pre-approval inspection as well as routine GMP compliance inspection for marketed products. The inspection scope covered products including inclisiran sodium, semaglutide, clascoterone, and brivaracetam. The announcement showed that inclisiran sodium is an active pharmaceutical ingredient used to treat adult primary hypercholesterolemia, with global sales of approximately 1.198 billion U.S. dollars in 2025; semaglutide is used for glucose lowering and weight reduction, with global sales of approximately 36.1 billion U.S. dollars in 2025.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.

Aurisco announced that it recently received a Drug GMP Compliance Inspection Notification issued by the Zhejiang Medical Products Administration, confirming that its eplerenone active pharmaceutical ingredient production line meets the requirements of Good Manufacturing Practice for Drugs. The inspection took place from May 13 to May 15, 2026, covering Workshop 804 and the EPLC production line. Eplerenone tablets are mainly used to treat heart failure and hypertension, with hospital-end sales of 1.77 million yuan in 2025. Passing the inspection helps the company maintain product quality and production capacity. In the first quarter of 2026, Aurisco achieved revenue of 389 million yuan and net profit attributable to the parent company of 63.93 million yuan.